ABOUT ONCOBIX
ONCOBIX's objective is to develop innovative targeted therapies.
Since its establishment in 2016, ONCOBIX has continuously researched the 4th-generation of
NSCLC therapies and others.
We aim to become a global leader in innovative drug discovery and provide
solutions to diseases with no standard treatment at the moment, thereby contributing to the health and
well-being of mankind.
R&D
Target-Oriented
Focused Pool (TOFPOMICS®)
TOFPOMICS® which is a main technology has dramatically improved existing technology in terms of required equipment, time, and cost. It is an innovative and competitive technology that, unlike HTS, can perform localized analyses of the target protein sites.
View More
Pipeline
OBX02 SERIES
ONCOBIX has pipelines for NSCLC treatment overcoming resistance to the 3rd-generation drugs, pulmonary fibrosis treatment, and pancreatic/liver cancer treatments.
View More
MISSION & VISION
ONCOBIX's Mission and Vision
-
Mission
Developing innovative new drugs based on platform technology to contribute to the health and well-being of humanity
-
Vision
Presenting solutions to unmet needs of rare, incurable diseases
- No posts found.